Ancestry invests in educating doctors about genetic testing October 30, 2019 -- Ancestry is set to offer educational information on the interpretation of genetic testing results for physicians in early 2020 through a $1 million grant to UpToDate, a clinical decision-support tool from Wolters Kluwer.
IGeneX reports data for tick-borne fever test October 30, 2019 -- Lyme disease specialist IGeneX has reported high sensitivity with a low risk for false positives in a study of its new immunoblot test for tick-borne relapsing fever.
PerkinElmer kicks off Vanadis prenatal testing October 29, 2019 -- PerkinElmer announced that it is starting to process blood samples using its Vanadis noninvasive prenatal testing system for genetic anomalies at its CLIA lab in Pittsburgh and also at an affiliate lab in Kuala Lumpur, Malaysia.
Roche Diagnostics appoints new CEO October 28, 2019 -- Roche Diagnostics has appointed Matthew Sause as president and CEO of North American operations, effective November 4.
NYU Langone launches genetic profiling of brain tumors October 28, 2019 -- NYU Langone Health announced that it has become the first CLIA-certified lab in the U.S. to get state approval to provide whole genome DNA methylation profiling for diagnosing and classifying brain tumors.
Hardy Diagnostics launches 15-minute resistance test October 25, 2019 -- Hardy Diagnostics has launched a multiplex immunoassay for detecting the five most common carbapenemase enzymes produced by Enterobacteriaceae and Pseudomonas aeruginosa from bacterial cultures through a distribution deal with the assay's manufacturer, NG Biotech.
RNA testing clarifies the unknown in Ambry cancer study October 25, 2019 -- RNA analysis helped clarify the significance of genetic variants associated with hereditary cancers that were inconclusive based on DNA testing alone in a retrospective study from Ambry Genetics published online October 23 in JAMA Network Open.
Myriad's myChoice PARP companion test clears FDA October 24, 2019 -- Myriad Genetics' myChoice CDx has received U.S. Food and Drug Administration (FDA) premarket approval as a companion diagnostic to guide the use of GlaxoSmithKline's poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula) in a new indication for heavily pretreated ovarian cancer.
LabCorp joins forces with Ind. nonprofit October 24, 2019 -- LabCorp has acquired the diagnostic clinical laboratory assets of the Indiana-based nonprofit South Bend Medical Foundation (SBMF) and will be providing advanced pathology services to SBMF customers in the region as part of a new collaboration.